Understanding Antibody-Drug Conjugates and Their Use in the Treatment of Breast Cancer With Ian Krop, MD, PhD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.

This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.  

Continue reading

Roy Herbst, MD, PhD: Adjuvant Osimertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Recently, the FDA approved osimertinib (Tagrisso®, AstraZeneca) as the first adjuvant therapy for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In this interview, Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and lead investigator of the ADAURA trial, on which the approval was based, speaks with i3 Health about the significance of the approval of osimertinib for this patient populati...

Continue reading

Pembrolizumab Still Effective After Five Years for Advanced Non-Small Cell Lung Cancer

Results of the KEYNOTE-010 study (NCT01905657) have shown that pembrolizumab is more effective than docetaxel for patients with previously treated, advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. However, what do the results look like after long-term follow-up? According to a study presented this past weekend at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, pembroli...

Continue reading

Adjuvant Osimertinib Approved for EGFR-Mutated Non-Small Cell Lung Cancer

The FDA has approved osimertinib (Tagrisso®, AstraZeneca) for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Previously approved for the first-line treatment of metastatic EGFR-mutated disease, osimertinib is the first adjuvant therapy to be approved for patients with EGFR-mutated NSCLC. The approval was based on the phase 3 ADAURA trial (NCT02511106). "Approximately 30% o...

Continue reading

Ramucirumab/Pembrolizumab in Patients With NSCLC, Gastric Cancer, or Urothelial Carcinoma

A phase 1a/b trial (NCT02443324) reports that ramucirumab in conjunction with pembrolizumab is effective in patients with previously treated advanced non-small cell lung cancer (NSCLC), gastroesophageal cancer, or urothelial carcinomas. Ramucirumab, a monoclonal antibody, blocks vascular endothelial growth factor receptor 2 (VEGFR2), which allows cancer cells to grow and metastasize. Pembrolizumab is also a monoclonal antibody, but it works by blocking programmed cell death protein-1 (PD-1), in ...

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.